Browse the evidence

Non-invasive mechanical ventilation (NIV) is superior to Continuous Positive Airway Pressure (CPAP) for treating Obesity Hypoventilation Syndrome (OHS) in patients without severe Obstructive Sleep Apnea (OSA), as CPAP fails to adequately correct daytime hypercapnia in this subgroup.

If you have Obesity Hypoventilation Syndrome but do not have severe sleep apnea, standard CPAP machines may not be enough to fix your high carbon dioxide levels. You likely need Non-Invasive Ventilation (NIV), which actively helps you breathe out more CO2. This is the standard of care for your specific profile.

Mandatory structured lifestyle modification programs prior to metabolic surgery do not improve post-operative outcomes and may cause harm by delaying access to surgery.

If you are being told you must complete a mandatory weight loss program before surgery, understand that this is likely a bureaucratic or insurance barrier, not a medical necessity. The evidence shows these programs do not improve surgical outcomes and may delay life-saving treatment. Seek a second opinion from a surgeon who follows modern guidelines that do not mandate pre-surgical weight loss.

SGLT2 inhibitors reduce the risk of hospitalization for heart failure and all-cause mortality in patients with type 2 diabetes compared to DPP-4 inhibitors.

If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors (like empagliflozin). They are proven to lower the risk of heart failure hospitalization and death more effectively than DPP-4 inhibitors, offering significant cardiovascular protection beyond just blood sugar control.

Maternal obesity during the first trimester of pregnancy increases the risk of congenital heart defects and cardiovascular issues in offspring, mediated in part by maternal pregestational diabetes.

For women planning pregnancy, managing weight and blood sugar before conception is critical to protecting the child's long-term heart health. This is a preventative measure that starts before pregnancy.

Higher deficit accumulation frailty index (FI) scores are strongly associated with increased total health care costs, including medication, outpatient, and hospitalization expenses, in adults with type 2 diabetes and overweight/obesity.

For individuals with type 2 diabetes and obesity, monitoring for 'frailty' (defined as the accumulation of health deficits like blood pressure, mobility issues, and chronic conditions) is critical. Higher frailty scores predict significantly higher medical bills. Interventions that slow the progression of frailty, such as the intensive lifestyle intervention in this study, can lead to substantial annual savings in healthcare costs ($437-$461/year), primarily through reduced medication and hospitalization needs.

Lasting remission of type 2 diabetes is not feasible in real-world settings due to the progressive nature of the disease, lack of consensus on definitions, and high rates of weight regain and treatment discontinuation.

Do not expect type 2 diabetes to be 'cured' or stay in remission without ongoing effort. Biological mechanisms will push your body to regain weight and increase hunger. Focus on sustainable management rather than a one-time fix, and maintain regular monitoring of cardiovascular and microvascular health even if your glucose levels are normal.

GLP-1 agonists and bariatric surgery can achieve high rates of remission, but these are not true remission as they require ongoing treatment, and long-term sustainability is low without continuous intervention.

GLP-1 agonists and surgery are effective for achieving remission, but they are not cures. You will likely need to continue treatment or accept the risks of surgery. Discuss with your doctor whether the benefits of these interventions outweigh the need for ongoing management.

Among adults aged 50 and older with newly diagnosed type 2 diabetes, the prevalence of undiagnosed (silent) hypertension reaches 50%, significantly higher than in younger diabetic cohorts.

If you are over 50 and have just been diagnosed with type 2 diabetes, you have a 1 in 2 chance of having high blood pressure that you don't know about. Because you likely have no symptoms, you must get your blood pressure checked immediately at diagnosis to prevent long-term heart and kidney damage.

In older adults (≥50 years) with newly diagnosed type 2 diabetes, mean systolic blood pressure often remains below the clinical hypertension threshold (140 mmHg) despite a high prevalence of silent hypertension, indicating subclinical vascular changes.

If you are over 50 with type 2 diabetes, do not assume your blood pressure is safe just because it is under 140 mmHg. Your blood vessels may already be stiffening, and your risk for heart disease is high even without a formal hypertension diagnosis. Monitor your BP closely and manage other risk factors like cholesterol and weight.

Age, BMI, HbA1c, family history of hypertension, and waist circumference are independent predictors of silent hypertension in newly diagnosed type 2 diabetes patients.

Your risk of having undiagnosed high blood pressure when you get diabetes depends on your age, weight, blood sugar control, family history, and waist size. If you have these risk factors, you are more likely to have silent hypertension and should be screened aggressively.

SGLT2 inhibitors provide significant cardiovascular and renal protection in type 2 diabetes patients through mechanisms independent of glycemic control, including metabolic reprogramming and fuel switching.

If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors. They protect your heart and kidneys through mechanisms beyond just lowering blood sugar, such as helping your body use different fuels. This can significantly reduce your risk of serious complications.

In patients with type 2 diabetes, the magnitude of weight loss achieved through semaglutide treatment (ranging from no loss to >10% loss) does not correlate with the risk of major adverse cardiovascular events (MACE), indicating that the drug's cardioprotective effects are independent of weight reduction.

If you are taking semaglutide for type 2 diabetes and cardiovascular risk, do not stop the medication if you are not losing as much weight as expected. The drug provides cardiovascular protection through direct effects on your blood vessels and heart, independent of how much weight you lose. Focus on the long-term heart health benefits rather than the number on the scale.

Postprandial glucose metabolism parameters derived from an Oral Glucose Tolerance Test (OGTT) do not predict anthropometric changes (weight, fat mass, or fat-free mass) following an 8-week low-calorie formula diet in adults with obesity.

If you are on a strict, low-calorie diet for 8 weeks, your body's specific glucose and insulin response to a sugar test (OGTT) will not help predict how much weight you will lose. The study found that baseline fat-free mass and sex were much better predictors of weight loss than metabolic phenotyping. Focus on adhering to the caloric deficit rather than seeking metabolic tests to guide short-term weight loss.

Conversional surgeries (e.g., RYGB, SADI-S, DS) are effective for managing post-bariatric recurrent weight gain (RWG) and diabetes recurrence, but carry higher risks of complications compared to primary surgery.

If you are gaining weight back after bariatric surgery and other treatments have failed, ask your doctor about conversional surgeries. These are more complex procedures that can effectively manage weight and diabetes, but they carry higher risks of complications. It is crucial to go to specialized centers with experienced surgeons and undergo strict postoperative surveillance.

Very low-carbohydrate diets (ketogenic) pose long-term sustainability, health, and environmental risks, including potential nutrient deficiencies and increased LDL cholesterol.

Be cautious with very low-carb diets. They can lead to nutrient deficiencies, increased LDL cholesterol, and are difficult to sustain long-term. Focus on balanced, high-quality diets instead.

High intake of linoleic acid (LA) does not impair the conversion of alpha-linolenic acid (ALA) to long-chain omega-3s (EPA/DHA) to a clinically significant degree, and the ratio of LA to ALA is less important than absolute intake levels.

You do not need to restrict seed oils to improve your omega-3 status. If you want more EPA/DHA, eat fish or algae supplements directly, as the body's conversion from plant sources (ALA) is inefficient regardless of how much seed oil you eat.

Menstrual cycle phase (follicular vs. luteal) and oral contraceptive use (active vs. placebo) do not significantly influence substrate oxidation (carbohydrate and fat ratios) at rest or during moderate-intensity continuous exercise.

You do not need to adjust your carbohydrate or fat intake based on where you are in your menstrual cycle or whether you are on birth control. The science shows that fuel oxidation remains consistent across phases. Focus on consistent nutrition and training intensity rather than trying to 'hack' your cycle for metabolic changes.

Higher community population density and greater impervious surface area (urbanization metrics) are associated with significantly lower total physical activity levels in adults.

If you live in a dense urban area, be aware that your total daily movement is likely lower than in rural areas, even if you have access to gyms. To counteract this, you must intentionally incorporate active transport (walking/cycling) and avoid sedentary occupational habits, as urbanization naturally suppresses household and occupational activity.

The central nervous system (CNS) acts as a fundamental regulator of glucose homeostasis by establishing a biologically defended level of glycemia (BDLG), and dysfunction in CNS control mechanisms contributes to the pathogenesis of type 2 diabetes (T2D) independently of pancreatic beta cell failure.

Current diabetes treatments often fail to achieve long-term remission because they only address insulin levels, ignoring the brain's role in setting a 'defended' high blood sugar level. Effective management may require strategies that address central nervous system regulation of glucose, not just pancreatic insulin output.

Most dietary (poly)phenols are not absorbed intact in the small intestine but pass to the colon where gut microbiota catabolize them into absorbable metabolites, which then enter circulation and exert biological effects.

Eat a variety of plant-based foods rich in polyphenols (berries, tea, coffee, onions, citrus). You do not need to worry about the 'bioavailability' of the raw compound because your gut bacteria process them into active metabolites that enter your bloodstream. The specific benefits depend on your unique gut microbiome, so diversity in your diet helps ensure you have the right bacteria to process different polyphenols.

Higher central adiposity (measured by waist-to-hip ratio) causally increases the risk of kidney stone disease, mediated in part by elevated serum calcium concentrations.

Maintaining a healthy waist circumference is more critical for preventing kidney stones than general weight loss alone. Central fat raises serum calcium, which increases stone risk. Focus on reducing visceral fat through lifestyle changes to lower this specific biochemical risk.

Successful weight loss and reversal of insulin resistance via combined nutritional and exercise interventions do not restore mitochondrial homeostasis in visceral adipose tissue (VAT), which remains characterized by irreversible mitochondrial dysfunction and metabolic plasticity breakdown.

For individuals who have successfully lost weight and improved insulin sensitivity, it is crucial to understand that visceral fat may retain permanent structural and functional damage (mitochondrial failure) from previous obesity. This means that while systemic health markers improve, the tissue itself may remain metabolically rigid. Continued lifestyle maintenance is essential not just for weight control, but to manage this residual tissue vulnerability.

Inclusion of genetic risk information in personalized nutrition advice does not significantly improve dietary changes, lifestyle behaviors, or weight loss outcomes compared to generic advice.

Do not pay for expensive genetic testing to guide your diet. Large studies show that knowing your genetic risk for obesity or diabetes does not help you lose weight or eat better than standard healthy eating advice. Focus on proven behavioral strategies like tracking intake and physical activity instead.

Epigenetic modifications (DNA methylation) associated with obesity and diet are largely consequences of the phenotype or acute events rather than causal factors.

Do not pay for 'biological age' tests based on DNA methylation. These changes are often just markers of your current health status, not something you can easily 'fix' with a specific supplement or diet. Focus on proven healthy habits.